Skip to main content
HR 6279 117th Congress House Health Administrative law and regulatory procedures Cardiovascular and respiratory health Congressional oversight Department of Health and Human Services Drug therapy Drug trafficking and controlled substances Drug, alcohol, tobacco use Emergency medical services and trauma care Government information and archives Government studies and investigations Health care coverage and access Infectious and parasitic diseases Licensing and registrations Prescription drugs

Opioid Treatment Access Act of 2022

Introduced: December 14, 2021 Introduced by: Norcross, Donald Democratic · New Jersey See on congress.gov
Sign in to write a letter Sign in to watch
 Everywhere this bill has been 4 steps
Introduced
In committee
Reported out
Passed House
Passed Senate
To President
Became law
Nov 1, 2022
Referred to the Subcommittee on Crime, Terrorism, and Homeland Security.
Dec 15, 2021
Referred to the Subcommittee on Health.
Dec 14, 2021
Referred to the Committee on Energy and Commerce, and in addition to the Committee on the Judiciary, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
Dec 14, 2021
Introduced in House
 Plain-English summary Congressional Research Service

Opioid Treatment Access Act of 2022

This bill expands access to substance use disorder treatment by modifying the regulation of opioid treatment programs and narcotic drugs used for treatment, including with respect to a patient's unsupervised use of such drugs.

Specifically, the Department of Health and Human Services (HHS) must issue regulations to further increase patients' access to unsupervised use or handling of drugs for treatment. The Substance Abuse and Mental Health Services Administration (SAMHSA) must study the effects of these revisions, and HHS must, as appropriate, promulgate additional regulations based on the study's findings.

SAMHSA must also study the impact of certain exemptions from certification requirements for opioid treatment programs that were granted as part of COVID-19 response efforts, including any additional costs or savings that resulted from the exemptions.

The bill also (1) allows specified types of health care providers to prescribe (subject to certain requirements) methadone that is dispensed through pharmacies for a patient's unsupervised use, and (2) provides statutory authority for a regulation that allows registered opioid treatment programs to operate mobile medication units without separately registering the unit.

What's happening now November 1, 2022

Referred to the Subcommittee on Crime, Terrorism, and Homeland Security.

 Committees of jurisdiction 4
 Cosponsors 1
All 1 Republican 1